LR Health & Beauty SE announced its financial results for the fourth quarter and full year 2024. Fourth quarter sales increased by 8% year-over-year to $80 million with an EBITDA of $8.7 million. Sales for the full year 2024 saw a 4.6% year-over-year increase, totaling $303 million, with an EBITDA of $28 million.
The company stated that it experienced “one-off extraordinary effects related to the realignment of the career plan in the fourth quarter and the early refinancing of the bond in spring 2024.” Both created a negative impact on earnings development in the financial year.
“LR Group’s strong growth is confirmation that we are on the right track with our strategy,” said Dr. Andreas Laabs, LR Health & Beauty SE CEO. “The positive performance in the final quarter of 2024 is primarily the result of the realignment of the career plan and the successful market launch of further product innovations. We’re constantly working to create the best possible conditions for the business success of our partners, who participated with great enthusiasm in a wide range of kick-off events at the beginning of the year. With LR ZEITGARD Signature, we have perfectly complemented our portfolio in the area of color cosmetics. We are confident that this solid foundation will enable us to continue our growth trajectory in the year of LR’s 40th anniversary.”
